Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxin Shengmai Granules for Stable Angina in Coronary Heart Disease
ChiCTR2400088123Phase 4Completed
- Sponsor
- China Academy of Chinese Medical Sciences
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in stable angina and coronary arteriosclerosis comparing Yangxin Shengmai Granules with Placebo (Yangxin Shengmai Granule simulator) (2 arms). Primary endpoint: Withdrawal or reduction rate of nitroglycerin tablets after 4 weeks of treatment. Started Aug 2024; status: completed.
02
Drugs
Yangxin Shengmai
03
Conditions
stable anginacoronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2400088123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088123.